Perspectives of people with inherited retinal diseases on ocular gene therapy in Australia: protocol for a national survey

Abstract

IntroductionVoretigene neparvovec-rzyl (Luxturna) was approved by the Australian Therapeutic Goods Administration on 4 August 2020 for the treatment of biallelic mutations in the RPE65 gene, a rare cause of congenital...